mRNA cancer immunotherapies

Search documents
BioNTech SE(BNTX) - 2025 Q1 - Earnings Call Transcript
2025-05-05 12:00
BioNTech (BNTX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Speaker0 Welcome to BioNTech's First Quarter twenty twenty five Earnings Call. I would like to hand the call over to Michael Horowitz, Director of Investor Relations. Please go ahead. Speaker1 Thank you. Good morning and good afternoon. Thank you for joining BioNTech's First Quarter twenty twenty five Earnings Call. As a reminder, the slides we will be using during this call and the corresponding press release we issued this morning can be found ...
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025
Globenewswire· 2025-04-24 10:45
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech’s advanced priority oncology programs as well as th ...